The Effect of CUGP Fluid Management in Patients With Sepsis or Septic Shock
NCT ID: NCT06879249
Last Updated: 2026-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
118 participants
INTERVENTIONAL
2025-04-01
2026-01-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ultrasound Optimization of Initial Fluid Challenge in Sepsis
NCT04028102
Septic Shock Management Guided by Ultrasound: SEPTICUS Trial
NCT04728529
Guiding Fluid Resuscitation in Septic Shock: Ultrasound vs. Noninvasive Cardiac Output Monitoring
NCT07162857
Fluid Responseveness in Sepsis and Its Correlation to CVP
NCT05612529
De-resuscitation Informed by Ultrasound for Patients With Sepsis
NCT04921319
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CUGP group
In the CUGP group, ultrasonographic assessment was performed by a team of trained critical ultrasonography physicians at enrollment, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours thereafter, respectively.
critical ultrasonography
In the CUGP group, attending physicians utilized a designed fluid management strategy guided by ultrasonographic evaluation of the inner diameter of IVC, ejection fraction (EF) value and passive leg raising-induced changes in VTI (ΔVTI). This ultrasonographic assessment was performed by a team of trained critical ultrasonography physicians at enrollment, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours thereafter, respectively. Additionally, patients did not preclude the concurrent use of conventional hemodynamic monitoring methods. At each of these time points, attending physicians would make comprehensive decisions on fluid management based on the results of ultrasonographic evaluation, along with other monitoring methods. The researcher recorded the basis of decisions, disposal strategy and outcomes.
usual care group
The usual care group used conventional hemodynamic monitoring methods for monitoring and decision-making about fluid management. Records were made at enrollment, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours thereafter, respectively.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
critical ultrasonography
In the CUGP group, attending physicians utilized a designed fluid management strategy guided by ultrasonographic evaluation of the inner diameter of IVC, ejection fraction (EF) value and passive leg raising-induced changes in VTI (ΔVTI). This ultrasonographic assessment was performed by a team of trained critical ultrasonography physicians at enrollment, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours thereafter, respectively. Additionally, patients did not preclude the concurrent use of conventional hemodynamic monitoring methods. At each of these time points, attending physicians would make comprehensive decisions on fluid management based on the results of ultrasonographic evaluation, along with other monitoring methods. The researcher recorded the basis of decisions, disposal strategy and outcomes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. Estimated length of ICU stay ≥ 24 hours;
* 3\. Diagnosis according to the Sepsis 3.0 criteria, which included:
* a. suspected or confirmed infections supported by clinical evidence and/or positive microbiological findings;
* b. the sepsis related organ failure assessment (SOFA) score ≥ 2.
Exclusion Criteria
* 2\. Patients had acute coronary syndrome;
* 3\. Patients had acute pulmonary edema;
* 4\. Patients had status asthmatics;
* 5\. Patients had malignant arrhythmia;
* 6\. Patients had active gastrointestinal bleeding;
* 7\. Patients had epileptic seizure;
* 8\. Patients had drug poisoning;
* 9\. Patients had severe burns;
* 10\. Patients had contraindications of blood transfusion;
* 11\. Patients had intra-abdominal hypertension (intra-abdominal pressure increases continuously ≥ 12mmHg);
* 12\. Patients had acute pulmonary embolism;
* 13\. Patients had contraindications of leg raising;
* 14\. Patients had cardiac structural or functional abnormalities (left ventricular outflow tract obstruction, moderate-to-severe mitral regurgitation, aortic regurgitation), it would seriously affect the velocity time integral of left ventricular outflow tract;
* 15\. Patients or their legal representatives refused active treatment;
* 16\. Patients or their legal representatives refused to participate in this study;
* 17\. Patients were participating in other interventional clinical trials.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shusheng Li
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shusheng Li
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shusheng Li, PhD
Role: PRINCIPAL_INVESTIGATOR
Tongji Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YLGX-ZZ-2020001
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
SEPSIS-CUGP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.